tulated to constrict sinusoids and, therefore, worsen portal hypertension (11, 30) , the mechanism by which activated HSCs augment contraction is not fully understood.
The mechanisms of contraction and relaxation in nonstriated muscles have been extensively studied in smooth muscle (10, 19, 23, 33, 34) . In smooth muscle cells, contractile force is generated by the interaction between actin and myosin, which is correlated with the phosphorylation levels of myosin light chain (MLC). MLC phosphorylation is known to be enhanced by Ca 2ϩ -dependent and/or Ca 2ϩ -sensitization pathways. In a Ca 2ϩ -dependent pathway, MLC is phosphorylated by activated MLC kinase (MLCK), whose activation is induced in response to an increase in intracellular Ca 2ϩ concentration ([Ca 2ϩ ] i ) and subsequent formation of the Ca 2ϩ /calmodulin complex. On the other hand, two major pathways for Ca 2ϩ sensitization have been proposed for inhibition of the activity of MLC phosphatase (MLCP), an enzyme that dephosphorylates phosphorylated MLC and induces relaxation. RhoA activates Rho kinase (ROCK), which phosphorylates myosin phosphatase targeting subunit 1 (MYPT1), an MLCP subunit, and inhibits MLCP activity (14, 39) . On the other hand, activation of protein kinase C (PKC) induces phosphorylation of the 17-kDa PKCpotentiated inhibitory protein, CPI-17 (13, 21) . Phosphorylated CPI-17 masks a catalytic subunit of MLCP, protein phosphatase-1c␦, leading to inhibition of MLCP activity (13, 14) . Thus inhibition of MLCP activity results in sustained MLC phosphorylation and powerful contraction at relatively low [Ca 2ϩ ] i levels.
In HSCs, contraction is known to be regulated by MLC phosphorylation in a manner analogous to contraction in smooth muscle cells (24, 40) . Some groups have pharmacologically implicated the presence of a Ca 2ϩ -sensitization pathway in HSCs (11, 17) . In addition, Laleman et al. (15) recently reported that both Ca 2ϩ -dependent and Ca 2ϩ -sensitization pathways are involved in rat HSC contraction. However, no reports have determined directly the Ca 2ϩ sensitization mechanism by which CPI-17 and MYPT1 regulate MLCP activity in HSCs, and also no reports are available examining the possible changes in the activities of these systems after HSC activation. The aim of this study was to elucidate the roles of CPI-17 and MYPT1 in enhancing MLC phosphorylation and contraction using in vitro and in vivo models of activated HSCs (25) .
MATERIALS AND METHODS
Isolation of HSCs. Animals were manipulated and cared for in strict compliance with the Guide to Animal Use and Care published by the University of Tokyo. The Institutional Review Board of the Graduate School of Agriculture and Life Sciences of the University of Tokyo approved the study protocol. Male Sprague-Dawley rats (500 -700 g) were anesthetized with pentobarbital (Kyoritsu, Nara, Japan). The liver was perfused through the portal vein with 0.67 mg/ml pronase E (Calbiochem, La Jolla, CA), followed by 0.33 mg/ml type I collagenase (Wako, Osaka, Japan). After perfusion, the liver was dissected and incubated in 0.5 mg/ml pronase E and 0.5 mg/ml type I collagenase at 37°C for 10 min and then centrifuged in 8.48% Nycodenz (Sigma, St. Louis, MO) gradients. Primary HSCs were cultured in plastic dishes in Dulbecco's modified Eagle's medium (Sigma), supplemented with 10% fetal bovine serum (JRH Biosciences, Lenexa, KS), 50 U/ml penicillin G (Invitrogen, Carlsbad, CA), and 50 g/ml streptomycin (Invitrogen) at 37°C under 5% CO 2. The medium was changed every 3 days. Characterization of HSCs was performed as described elsewhere (2); i.e., primary HSCs were identified by the presence of lipid droplets and blue autofluorescence upon ultraviolet exposure. The purity of primary isolated HSCs was Ͼ95%. HSCs were cultured for 1, 4, and 7 days after isolation and used in the following experiments.
Cirrhotic animal model. Male Sprague-Dawley rats (350 -400 g) were anesthetized with pentobarbital. Bile duct ligation (BDL) rats underwent a midline incision, double ligation of the common bile duct, and excision of the bile duct between the knots, whereas sham rats underwent midline incision and manipulation of the common bile duct without ligation. BDL and sham rats were killed 2 wk after surgery. Dimethylnitrosoamine (DMN) rats were intraperitoneally injected with DMN (10 mg/kg) every 3 days for 2 wk, whereas saline rats were injected with saline. DMN and saline rats were killed 4 days after the last injection. Primary HSCs were isolated from cirrhotic rats and control rats using the aforementioned protocol, cultured for 2 days, and used for the following experiments.
Immunofluorescent staining. Primary HSCs were fixed with 4% paraformaldehyde at 37°C for 5 min. HSCs were permeabilized with 0.1% Triton-X 100 for 10 min, blocked with 5% skim milk for 1 h, and treated with anti ␣-SMA antibody (1:200; DakoCytometion) at 4°C overnight. The cells were treated with rabbit anti-mouse antibody conjugated to Alexa Fluor 568 (1:200; Invitrogen) for 1 h in the dark, followed by treatment with 1 g/ml 4,6-diamidino-2-phenylindole (Wako) for 5 min. Fluorescence was observed using fluorescent microscopy (ECLIPSE E800, Nikon, Tokyo, Japan).
Immunohistochemistry and Masson-Trichrome staining. Liver specimens from cirrhotic and control rats were routinely fixed with 4% paraformaldehyde overnight, embedded in paraffin, and sectioned at 6 m. Some liver sections were routinely stained with MassonTrichrome. For immunohistochemistry, liver sections were autoclaved at 121°C for 5 min, treated with 3% hydrogen peroxide for 10 min, blocked with 5% skim milk for 1 h, and treated with anti-␣-SMA antibody (1:200) at 4°C overnight. The sections were treated with horse anti-mouse IgG antibody conjugated to biotin (1:250; Vector Laboratories, Burlingame, CA) for 1 h, and then with StreptABComplex/HRP (Dako) for 30 min, followed by treatment with 0.2 mg/ml diaminobenzidine solution and counterstaining.
Quantitative RT-PCR. Total RNA was extracted with TRIzol (Invitrogen), and reverse transcription was performed using SuperScriptIII reverse transcriptase (Invitrogen). Quantitative RT-PCR was performed using Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen) and the 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA), according to the manufacturer's instructions. mRNA expression was normalized to 18S rRNA. The sequences of the primers used are shown in Table 1 .
Western blotting. Primary HSCs were lysed with lysis buffer [60 mM ␤-glycerophosphate, 50 mM Tris·HCl (pH 8.0), 2 mM EGTA, 1 mM sodium orthovanadate, 0.2% SDS, and 0.5% Nonidet P-40]. The lysed samples were placed on ice for 30 min and centrifuged at 20,000 g for 15 min. Total protein (10 g) was applied to each well of 7.5 or 15% acrylamide gels and electrophoresed at 100 V for 1 h. The proteins were transferred to a polyvinylidene difluoride membrane at 400 mA for 3 h and blocked with 3% BSA for 30 min. The membrane was treated with the following primary antibodies at 4°C overnight [anti-␣-SMA antibody (1:2,000), anti-␤-actin antibody (1:4,000; Sigma), anti-MLCK antibody (1:1,000, Sigma), anti-CPI-17 antibody (1:1,000; Upstate, VA), and anti-ROCK2 antibody (1:1,000; Santa Cruz, Santa Cruz, CA)]. The membrane was treated for 1 h with the following secondary antibodies as appropriate [goat anti-mouse IgG antibody conjugated to IRDye 800 (Rockland, PA) and goat antirabbit IgG or donkey anti-goat IgG antibodies conjugated to Alexa Fluor 680 (Invitrogen)]. The fluorescent signals were detected using an Infrared Imaging System (LI-COR, Lincoln, NE). The band density was normalized to ␤-actin.
Analysis of MLC, CPI-17, and MYPT1 phosphorylation. Primary HSCs were starved for 1 day, pretreated with or without kinase inhibitors for 30 min, and stimulated with endothelin-1 (ET-1) (Peptide Institute, Osaka, Japan). After stimulation, the cells were washed with cold PBS once and treated with 10% TCA, 10 mM DTT to abolish phosphatase activity. The cells were harvested, rinsed with water-saturated diethyl ether three times, and dried in the freezer overnight. Protein was extracted using the same lysis buffer as described above, and then 10 g (MLC) or 20 g (CPI-17, MYPT1) of total proteins were loaded into each well of 7.5 or 15% acrylamide gels, electrophoresed, and blotted onto a polyvinylidene difluoride membrane. After blocking, the membrane was incubated with the following primary antibodies [anti-MLC antibody (1:2,000; a generous gift from Dr. J. Stull, University of Texas), anti-pMLC (phosphorylated MLC) antibody, specific for Thr18/Ser19 (1:1,000; Santa Cruz), anti-CPI-17 antibody, anti-pCPI-17 (phosphorylated CPI-17) antibody, specific for Thr38 (1:1,000; Santa Cruz), anti-MYPT1 antibody (1:1,000; Santa Cruz), anti-pMYPT1 (phosphorylated MYPT1) antibody, specific for Thr696 (1:1,000; Santa Cruz), and anti-pMYPT1 antibody, specific for Thr853 (1:1,000; Upstate)]. The membrane was treated for 1 h with the secondary antibodies, and fluorescent signals were detected using Odyssey Imaging System (Li-Cor Biosciences, Lincoln, NE).
Measurement of [Ca 2ϩ ]i. [Ca 2ϩ ]i was measured using fura-2. Cells were loaded with 3 M fura-2 AM for 45 min at 37°C. Using a fluorescence imaging system (Hamamatsu Photonics, Hamamatsu, Japan), images were obtained every 3 s, and fluorescence of the image at 340 nm (F340) was divided by fluorescence of the image at 380 nm (F380) to produce the F340-to-F380 ratio.
Gel contraction assay. Primary HSCs (1.5 ϫ 10 5 ) were seeded onto a collagen lattice (Nitta Gelatin, Tokyo, Japan) in a 12-well plate. The lattice was incubated in serum-free medium for 1 day and detached from the well. The lattice was photographed at 0 and 30 min after ET-1 stimulation. The lattice area was measured using National Institutes of Health Image J software.
Measurement of hydroxyproline. The hydroxyproline concentration in the whole liver was measured as previously described (26) .
Statistical analyses.
Results are expressed as means Ϯ SE. The statistical difference was determined with Student's t-test for comparison between two groups or with one-way ANOVA followed by Dunnett's multiple-comparison test for comparison among three or more groups. Differences with P Ͻ 0.05 were considered significant (*P Ͻ 0.05, **P Ͻ 0.01).
RESULTS

Morphological characteristics and expression of regulatory proteins for contraction in HSCs.
Primary HSCs become spontaneously activated and accelerate expression of ␣-SMA when cultured in vitro (7) . In this study, the presence of primary HSCs was confirmed by observing autofluorescence of lipid droplets containing vitamin A (Fig. 1A) . Anti-␣-SMA antibody staining demonstrated that HSCs at day 1 were still quiescent, whereas HSCs at days 4 and 7 had become myofibroblast-like cells, consistent with their activated form (Fig.  1B) . Consistent with these morphological observations, expression of ␣-SMA (mRNA and protein) was increased during HSC activation (Fig. 1C) . Expression of MLCK was also increased after HSC activation at mRNA and protein levels (Fig. 1D) .
To investigate the expression pattern of MLCP components and their regulatory proteins during HSC activation, quantita- tive RT-PCR was performed. Expression of CPI-17 and ROCK2 mRNA in HSCs at day 7 was increased compared with expression at day 1 (Fig. 1, E and F) , whereas expression of RhoA, ROCK1, protein phosphatase 1, and MYPT1 mRNA was unchanged (data not shown). In parallel with the mRNA expression, an increase in protein expression of CPI-17 ( Fig.  1E) and ROCK2 (Fig. 1F ) was confirmed using Western blotting.
Phosphorylation of CPI-17. Contraction of HSCs is elicited by ET-1, a powerful vasoconstrictor (12, 29, 35, 42) , which is produced by sinusoidal endothelial cells and HSCs (28) . ET-1 is increased in human plasma (18, 36) and in the cirrhotic livers of rats (28) and humans (24) . Taken together with the observations shown in Fig. 1 , we hypothesized that ET-1 induces phosphorylation of CPI-17 at Thr38 in culture-activated HSCs, which suppresses MLCP activity. As expected, ET-1 (1-100 nM) induced phosphorylation of CPI-17 at Thr38 in a concentration-dependent manner ( Fig. 2A) . Phosphorylation of CPI-17 at Thr38 was increased at 1 min, and this phosphorylation was maintained for at least 30 min (Fig. 2B) . Inhibitors of PKC and ROCK are known to suppress CPI-17 phosphorylation in smooth muscle cells (13) . Phosphorylation of CPI-17 at Thr38 was abrogated by Ro-31-8425 (1 M), PKC inhibitor (6), and K252a (1 M), potent and nonselective kinase inhibitor (20) , and was partially inhibited by Y-27632 (1 M), ROCK inhibitor (37) (Fig. 2C) . Phosphorylation of MYPT1. MLCP in smooth muscle cells is also regulated by phosphorylated MYPT1 at Thr696 and Thr853 (numbering is according to the residue number of human MYPT1) (14, 21) . In culture-activated HSCs, phosphorylation levels of MYPT1 at Thr696 were unchanged after the addition of ET-1 (1-100 nM) (Fig. 3, A and C) . In contrast, phosphorylation of MYPT1 at Thr853 was induced by ET-1 (1-100 nM) in a concentration-dependent manner (Fig. 3B) . The rate of increase in MYPT1 phosphorylation at Thr853 was rapid and was maintained for 30 min (Fig. 3C) . MYPT1 phosphorylation at Thr853 in smooth muscle cells has been reported to be catalyzed by ROCK (14) . As expected, phosphorylation of MYPT1 at Thr853 due to ET-1 was inhibited by individual treatment with Y-27632 (1 M) or K252a (1 M) (Fig. 3D) . Furthermore, Ro-318425 alone failed to inhibit MYPT1 phosphorylation at Thr853, and a combination of Ro-31-8425 and Y-27632 inhibited MYPT1 phosphorylation to a level in the presence of Y-27632 alone (data not shown).
Phosphorylation of MLC. ET-1 binds to two types of ET receptors, ET A and ET B receptors (31) . Although both receptors are expressed in HSCs (7), only the ET A receptor is upregulated in HSCs in the cirrhotic rat liver (41) . Consistent with these reports, ET-1 (1-100 nM) increased [Ca 2ϩ ] i in a dose-dependent manner in culture-activated HSCs (Fig. 4A) . Pretreatment with the ET A -specific antagonist BQ-123 (3 M) Fig. 3 . ET-1 enhances phosphorylation of MLC phosphatase targeting subunit 1 (pMYPT1) at Thr853 via the ROCK pathway in culture-activated HSCs. HSCs were isolated from normal rats, cultured for 7 days, and starved for 1 day. A and B: culture-activated HSCs were stimulated with ET-1 (1-100 nM) for 2 min, and then phosphorylation of MYPT1 at Thr696 (A) and Thr853 (B) was measured by Western blotting (n ϭ 4 -5). C: culture-activated HSCs were stimulated with ET-1 (10 nM) for 0 -30 min, and then phosphorylation of MYPT1 at Thr696 and Thr853 was measured by Western blotting (n ϭ 4). D: culture-activated HSCs were pretreated with or without Y-27632 (1 M) or K252a (1 M) 30 min before stimulation with ET-1 (10 nM) for 2 min, and then phosphorylation of MYPT1 at Thr853 was measured by Western blotting (n ϭ 4 -5). MYPT1 phosphorylation level is expressed as a ratio to total MYPT1. Values are means Ϯ SE. *P Ͻ 0.05, **P Ͻ 0.01, compared with HSCs without ET-1. † †P Ͻ 0.01, compared with HSCs with ET-1.
greatly inhibited the transient increase in [Ca 2ϩ ] i (data not shown).
We next verified that ET-1 (1-100 nM) leads to HSC contraction in a dose-dependent manner in a gel contraction assay (Fig. 4B) . As contractility increased, ET-1 enhanced phosphorylation of MLC at Thr18/Ser19 (Fig. 4C) . MLC phosphorylation was enhanced by ET-1 (10 nM) and peaked at 1 min, which was decreased and maintained for at least 30 min (Fig. 4D) .
Our finding that ET-1 induced phosphorylation of CPI-17 and MYPT1 suggests the possibility of changes in MLCP activity to control MLC phosphorylation. Phosphorylation of ␤-Actin was used as a loading control to normalize expression of ␣-SMA, MLCK, CPI-17, and ROCK2. *P Ͻ 0.05, **P Ͻ 0.01, compared with HSCs isolated from saline-treated rats (n ϭ 4). F: contraction assay of HSCs using collagen lattices. HSCs were isolated from DMN and saline rats and cultured for 2 days. The cells were seeded onto collagen lattices and starved for 1 day, and then the lattices were photographed 30 min after stimulation with ET-1 (10 nM). Values are means Ϯ SE. **P Ͻ 0.01, compared with HSCs isolated from saline-treated rats (n ϭ 5-6).
MLC at Thr18/Ser19 was partially inhibited by individual treatment with Ro-31-8425 (1 M) or Y-27632 (1 M) (Fig.  4E) . Furthermore, MLC phosphorylation was decreased more when pretreated with a mixture of Ro-31-8425 and Y-27632 compared with Ro-31-8425 or Y-27632 alone, but was not completely abolished, indicating that further phosphorylation was possibly induced by MLCK in a Ca 2ϩ -dependent pathway. ML-7 (10 M), MLCK inhibitor (38) , alone reduced MLC phosphorylation in culture-activated HSCs (Fig. 4F) . Pretreatment with a combination of Ro-31-8425, Y-27632, and ML-7 decreased the level of MLC phosphorylation to a level similar to that with K252a (Fig. 4G) .
Upregulation of MLCK, CPI-17, and ROCK2 in activated HSCs isolated from DMN-treated rats.
Because culture-activated HSCs upregulated MLCK, CPI-17, and ROCK2, we tested whether activated HSCs in the liver of DMN-treated cirrhotic rats upregulated the expression of these molecules. Masson-Trichrome staining showed that collagen deposition in the liver was increased in rats subjected to DMN treatment compared with saline-treated rats (Fig. 5A) . The amount of hydroxyproline in the liver was increased in DMN-treated rats relative to saline-treated rats (data not shown). ␣-SMA-positive cells were also increased in DMN rats (Fig. 5B) . To confirm that these ␣-SMA-positive cells in the injured liver were activated HSCs, HSCs were isolated from DMN rats. HSCs isolated from DMN rats (named DMN-HSCs) were larger in size and had fewer lipid droplets compared with HSCs isolated from saline-treated rats (named saline-HSCs) (Fig.  5C ). DMN-HSCs were stained with anti-␣-SMA antibody (Fig.  5D) . DMN-HSCs showed increased expression of ␣-SMA, MLCK, CPI-17, and ROCK2 compared with saline-HSCs (Fig.  5E ). Because activated HSCs increase the constriction of hepatic sinusoids (7), we next performed a gel contraction assay and found that DMN-HSCs generated greater contractile forces than saline-HSCs when treated with ET-1 (10 nM) (Fig. 5F) .
Enhanced MLC phosphorylation in DMN-HSCs. To further investigate ET-1-induced Ca 2ϩ sensitization in DMN-HSCs, the phosphorylation levels of MLC, CPI-17, and MYPT1 were (Fig. 6A ). Combined treatment with Ro-31-8425 and Y-27632 more strongly inhibited MLC phosphorylation. Pretreatment with K252a (1 M) completely suppressed MLC phosphorylation. To investigate whether phosphorylation of CPI-17 and MYPT1 is involved in MLC phosphorylation in vivo, phosphorylation levels of CPI-17 and MYPT1 were measured in DMN-HSCs. In DMN-HSCs, ET-1 enhanced the phosphorylation of CPI-17 at Thr38, and this increase was inhibited by individual treatment with Ro-31-8425 or K252a (Fig. 6B) . ET-1 augmented phosphorylation of MYPT1 at Thr853, which was inhibited by individual treatment with Y-27632 or K252a (Fig. 6C) .
Upregulation of MLCK, CPI-17, and ROCK2 in HSCs isolated from BDL rats. To further understand the results obtained from the analysis of DMN-HSCs, BDL rats were generated as an additional cirrhotic animal model. Total bilirubin in serum was increased in BDL rats compared with that in sham rats (Fig. 7A) . Expression of ␣-SMA in the liver was upregulated in BDL rats compared with sham-operated rats (Fig. 7B) . Expression of ␣-SMA was also upregulated in HSCs isolated from BDL rats (named BDL-HSCs) relative to expression in HSCs isolated from sham rats (named sham-HSCs) (Fig. 7, C and D) . Furthermore, expression of MLCK, CPI-17, and ROCK2 was increased in BDL-HSCs compared with that in sham-HSCs (Fig. 7D) . In the presence of ET-1 (10 nM), BDL-HSCs acquired stronger contractile forces than shamHSCs (Fig. 7E ). These observations indicate that HSCs were similarly activated in the liver of BDL rats.
Enhanced phosphorylation of MLC in BDL-HSCs. Finally, we analyzed the phosphorylation levels of MLC, CPI-17, and MYPT1 using BDL-HSCs. In BDL-HSCs, ET-1 (10 nM) enhanced phosphorylation of MLC at Thr18/Ser19, which was partially inhibited by individual treatment with Ro-31-8425 (1 M) or Y-27632 (1 M) (Fig. 8A) . Pretreatment with both Ro-31-8425 and Y-27632 more strongly inhibited this phosphorylation. Pretreatment with K252a (1 M) abolished MLC phosphorylation. ET-1 enhanced phosphorylation of CPI-17 at Thr38, which was completely inhibited by individual treatment with Ro-31-8425 or K252a (Fig. 8B) . Conversely, ET-1 enhanced phosphorylation of MYPT1 at Thr853, which was inhibited by individual treatment with Y-27632 or K252a (Fig. 8C) .
DISCUSSION
In this study, we examined the dynamics of contractile regulatory proteins during HSC activation and the precise mechanism by which ET-1 induced contraction in HSCs. The main findings of this study are as follows: 1) culture-activated HSCs upregulated expression not only of MLCK, but also of CPI-17 and ROCK2; 2) ET-1 enhanced MLC phosphorylation in culture-activated HSCs via a Ca 2ϩ -sensitization pathway mediated by the PKC/CPI-17 and ROCK/MYPT1 pathways; and 3) activated HSCs isolated from cirrhotic rat livers exhibited similar enhanced contractile mechanisms as observed in culture-activated HSCs.
A crucial finding of this study is that increased MLC phosphorylation was associated with increased phosphoryla- tion of CPI-17 at Thr38 and phosphorylation of MYPT1 at Thr853, both of which may inactivate MLCP. Expression of CPI-17 was dramatically increased during HSC activation. ET-1-induced phosphorylation of CPI-17 at Thr38 was completely suppressed by the PKC inhibitor Ro-31-8425. In addition, ET-1 induced phosphorylation of MYPT1 at Thr853, which was greatly inhibited by the ROCK inhibitor Y-27632. Although we did not observe an elevation in MYPT1 expression during HSC activation, a marked increase in ROCK2 (which is predominantly expressed in smooth muscle) was detected, indicating that increased activity of RhoA/ROCK2 signaling may be responsible for an increase in MYPT1 phosphorylation.
To obtain more insight into the physiological roles of MLCP in regulating contraction in culture-activated HSCs, the effects of PKC and ROCK inhibitors on MLC phosphorylation were examined. As shown in Fig. 4 , a single application of Ro-31-8425 or Y-27632 moderately inhibited MLC phosphorylation at Thr18/Ser19 in the presence of ET-1. Combined application of these two inhibitors, however, additively inhibited MLC phosphorylation. These results suggest that activated HSCs may enhance MLC phosphorylation either through the PKC/ CPI-17 or ROCK/MYPT1 pathway.
We have previously tried to examine the inhibitory effects of PKC and ROCK (using Ro-31-8425 and Y-27632) on HSC gel contraction. Although inhibition of these kinases decreased HSC contraction induced by ET-1, the treatment with inhibitors, in either the presence or absence of ET-1, reduced HSC contraction finally to the same extent. These observations suggest that phosphorylation levels of CPI-17 and MYPT1 even at resting condition might be important for HSC contraction. Future study using short interfering RNA for CPI-17 or MYPT1 would reveal the precise regulatory mechanism for HSC contraction.
Activated HSCs in the cirrhotic liver proliferate, surround sinusoidal vessels, and enhance constriction, resulting in portal hypertension (16, 22) . Therefore, inhibition of excessive HSC contraction and induction of HSC relaxation may be reasonable treatments for portal hypertension (27) . In this study, DMN and BDL cirrhotic animals were employed to evaluate whether the results obtained from the in vitro study are reflected in vivo. Our observations showed that HSCs isolated from cirrhotic rats upregulated expression of ␣-SMA and CPI-17. Consistent with our present results, a microarray analysis study listed ␣-SMA and CPI-17 as genes that are upregulated in activated HSCs isolated from CCl 4 -treated and BDL mice (3) . We further demonstrated here that phosphorylation of CPI-17 in HSCs isolated from cirrhotic rats was completely abolished by Ro-31-8425, leading to a reduction in MLC phosphorylation. Additionally, a gel contraction assay clearly showed that HSCs isolated from cirrhotic rats increases their contractility after ET-1 stimulation relative to HSCs isolated from control rats. These results are consistent with those obtained from in vitroactivated HSCs. Based on these findings, activated HSCs in the cirrhotic liver appear to induce continuous contraction and constrict sinusoids, mainly through the Ca 2ϩ -sensitization pathway.
Another notable observation in this study is that CPI-17 expression was greatly upregulated in both in vitro-and in vivo-activated HSCs. CPI-17 has recently been suggested to be a protooncogene that is involved in tumor proliferation (9) . In the case of cirrhosis, CPI-17 in activated HSCs possibly induces not only contraction but also proliferation, resulting in exacerbation of cirrhosis. Based on these findings, inhibitors specific to CPI-17 may contribute to amelioration of cirrhosis.
In conclusion, we demonstrated here that culture-activated HSCs increase expression of regulatory proteins responsible for both Ca 2ϩ -dependent and Ca 2ϩ -sensitization pathways. Furthermore, this study showed that activated HSCs enhance MLC phosphorylation through increased phosphorylation of CPI-17 and MYPT1. In vivo-activated HSCs isolated from DMN and BDL cirrhotic rats increase MLC phosphorylation through mechanisms similar to culture-activated HSCs, supporting the notion that activated HSCs surrounding sinusoidal vessels constrict vessels and exacerbate cirrhosis through the Ca 2ϩ -sensitization pathway.
